Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus quadruple immunosuppression versus standard triple immunosuppression after lung transplantation
2011-001539-21Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of everolimus in Lung allograft rejection (LAR) (2 arms), sponsored by Novartis. Primary endpoint: Renal function at 12 months by cGFR using CKD-EPI. Started Aug 2011; status: completed.
02
Drugs
everolimus
03
Conditions
Lung allograft rejection (LAR)
Beyond the preview
Go deeper on 2011-001539-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001539-21.